TrialSignal
Clinical trial intelligence report
A Modular Phase I-II Trial of Lenalidomide and Paclitaxel in Men With Castration-Resistant Prostate Cancer and Lymph-Node Dominant Metastases
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT00933426
Status
TERMINATED
Phase
Phase I-II
Sponsor
M.D. Anderson Cancer Center
Executive brief
Investment-Ready Snapshot
This clinical trial aimed to evaluate the safety and efficacy of lenalidomide in combination with paclitaxel for men with castration-resistant prostate cancer. The study was conducted by M.D. Anderson Cancer Center and sponsored by Celgene Corporation. It was terminated early due to slow patient accrual.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT00933426
Indication
Prostate Cancer
Modality
small molecule
Target
Castration-Resistant Prostate Cancer
Intervention
Lenalidomide, Paclitaxel
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.